Skip to main content
Terug
Watch Compare

DiaMedica Therapeutics Inc.

Datakwaliteit: 83%
DMAC
Nasdaq Manufacturing Chemicals
€ 6,22
▲ € 0,03 (0,48%)
Marktkapitalisatie: 335,15 M
Prijs
€ 6,22
Marktkapitalisatie
335,15 M
Dagbereik
€ 5,85 — € 6,32
52-Weeksbereik
€ 3,28 — € 10,42
Volume
186.198
Openen € 6,20
50D / 200D Gem.
€ 7,76
19,85% below
50D / 200D Gem.
€ 6,79
8,45% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -29,10 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-83,17%
Onder sectorgemiddelde (-51,02%)
ROIC-68,68%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio10,67
Interest CoverageN/A

Waardering

PE (TTM)
-10,23
Onder sectorgemiddelde (-1,98)
P/B Ratio6,49
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (44 peers)
Metriek Aandeel Sector Mediaan
P/E -10,2 -2,0
P/B 6,5 5,1
ROE % -83,2 -51,0
Net Margin % — -150,2
Rev Growth 5Y % — 9,3
D/E — 0,3

ETFs Holding This Stock

AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -32,77 M
ROE -83,17% ROA -74,03%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -29,10 M
ROIC -68,68% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10,67
Interest Coverage N/A Asset Turnover N/A
Working Capital 50,96 M Tangible Book Value 51,62 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -10,23 Forward P/E N/A
P/B Ratio 6,49 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -8,68%
Market Cap 335,15 M Enterprise Value 331,82 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share -0,54 OCF / Share -0,54
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 88,82%
SBC-Adj. FCF -32,32 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -32,77 M -24,44 M -19,38 M -13,68 M -13,59 M
EPS (Diluted) — — — — —
Gross Profit — — — — —
Operating Income -34,40 M -26,68 M -21,27 M -14,00 M -13,65 M
EBITDA — — — — —
R&D Expenses 24,61 M 19,06 M 13,11 M 7,84 M 8,77 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 28.000,0 30.000,0 43.000,0 28.000,0 28.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 61,37 M 46,35 M 54,16 M 34,40 M 45,55 M
Total Liabilities — — — — —
Shareholders' Equity 56,11 M 40,72 M 51,06 M 31,83 M 44,02 M
Total Debt — — — — —
Cash & Equivalents 15,65 M 3,03 M 4,54 M 4,73 M 4,71 M
Current Assets 60,63 M 44,61 M 53,68 M 33,84 M 45,44 M
Current Liabilities 5,13 M 5,39 M 2,79 M 2,17 M 1,52 M